Acadesine (INN), also known as 5-aminoimidazole-4-carboxamide-1-??-D-ribofuranoside, AICA-riboside, and AICAR, is an AMP-activated protein kinase activator which is used recompense the treatment of grave lymphoblastic leukemia and may have applications in treating other disorders such as diabetes.

Acadesine is an adenosine regulating agent developed past PeriCor Therapeutics and licensed to Schering-Plough in 2007 for state III studies. The stimulant is a passive first-in-class spokesman repayment for intercepting of reperfusion injury in CABG surgery. Schering began steadfast enrollment in side III studies in May, 2009. The fling was terminated in delayed 2010 based on an interim futility analysis.